Capmatinib (Tabrecta)

Ingredients: Capmatinib
Dosage Form: Capsules
Innovator’s Brand Name: Tabrecta
Generic Brand Name: Pmatinib
Generic Manufacturer: Ziska Pharma

Indications:
Capmatinib is indicated for the treatment of metastatic non‑small cell lung cancer in patients whose tumors harbor MET exon 14 skipping mutations confirmed by an FDA‑approved test.

Dosage and Administration:
The recommended dose is 400 mg orally once daily, given in two 200 mg doses, with or without food. Swallow capsules whole; if a dose is missed or vomiting occurs, follow your healthcare provider’s guidance on when to take the next dose.

Adverse Reactions:
Common adverse reactions include respiratory disorders, hepatic or pancreatic function abnormalities, peripheral edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.

Storage:
Store in a cool, dry place at or below 25 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link